Compare · ARGX vs VCEL
ARGX vs VCEL
Side-by-side comparison of argenx SE (ARGX) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $49.78B, about 28.3x VCEL ($1.76B).
- Over the past year, ARGX is up 40.9% and VCEL is down 16.5% - ARGX leads by 57.3 points.
- ARGX has been more active in the news (6 items in the past 4 weeks vs 4 for VCEL).
- ARGX has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- argenx SE
- Vericel Corporation
- Price
- $812.95+1.32%
- $34.72+0.84%
- Market cap
- $49.78B
- $1.76B
- 1M return
- +0.24%
- -4.80%
- 1Y return
- +40.88%
- -16.46%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest VCEL
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Vericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $202,500 worth of shares (5,000 units at $40.50) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 21,009 units (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan sold $188,045 worth of shares (4,855 units at $38.73) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 1,118 units (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
- Director Wotton Paul K converted options into 3,200 shares, increasing direct ownership by 12% to 28,802 units (SEC Form 4)